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GENETIC DISORDERS – DEVELOPMENT
COL4A3 mutations and their clinical consequences in thin
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COL4A3 mutations and their clinical consequences in thin
basement membrane nephropathy (TBMN).
Background. Thin basement membrane nephropathy
(TBMN) is often caused by mutations in the COL4A3 and
COL4A4 genes.
Methods. We examined 62 unrelated individuals diagnosed
with TBMN by renal biopsy (N = 49, 79%) or a posi-
tive family history of hematuria but without a biopsy (N =
13, 21%) for mutations in the COL4A3 gene and the
COL4A3/COL4A4 promoter. All 52 exons of COL4A3 as well
as the COL4A3/COL4A4 promoter were screened with single-
stranded conformational polymorphism (SSCP) analysis at 4◦C
and at room temperature. Amplicons that demonstrated elec-
trophoretic abnormalities were sequenced.
Results. Seven mutations were demonstrated in seven pa-
tients: G532C and G584C in exon 25, G596R in exon 26,
G695R in exon 28, and IVS 2224 − 11C>T, IVS 2980 +
1G>A and IVS 3518 – 7C>G. No mutations were found in
the COL4A3/COL4A4 promoter. Four novel polymorphisms
or variants (P116T in exon 6, P690P in exon 27, and G895G
and A899A in exon 33) were also demonstrated. In addition,
P1109S and Q1495R, which had been described previously but
whose status was unclear, were shown to be polymorphisms.
All seven mutations described here were associated with hema-
turia. While one mutation (2980 + 1G>A) was found in an in-
dividual who also had proteinuria, none of her family members
with the same mutation had increased urinary protein. None
of the patients with these seven mutations had renal impair-
ment. Hematuria was completely penetrant in families with the
G532C, G584C, G596R, and IVS 2980 + 1G>A mutations but
not with the G695R and IVS 3518 − 7C>G mutations.
Conclusion. COL4A3 mutations are common in TBMN.
Thin basement membrane nephropathy (TBMN) oc-
curs in at least 1% of otherwise normal children and
adults [1, 2], and is usually characterized by persistent
dysmorphic hematuria, minimal proteinuria, normal re-
nal function, and an excellent prognosis. Ultrastructural
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examination of the renal biopsy in TBMN demonstrates
a uniformly thinned glomerular basement membrane
(GBM) [3]. Two thirds of affected individuals have an-
other family member with hematuria [4] and inheritance
in these families is autosomal dominant [5].
The demonstration of a thinned GBM in heterozygotes
from families with autosomal-recessive Alport syndrome
first suggested that TBMN might represent the carrier
state for this condition or at least be caused by muta-
tions in the same genes [abstract; Lambrecht R, et al, J
Am Soc Nephrol 7:1616A, 1996] [6–8]. Our laboratory
subsequently showed that nearly 40% of families with
biopsy-proven TBMN have hematuria that segregates
with the COL4A3/COL4A4 locus [4]. Furthermore, we
demonstrated identical COL4A4 mutations in carriers
of autosomal-recessive Alport syndrome and in TBMN
[9, 10] which confirmed that TBMN sometimes repre-
sents the carrier state for autosomal-recessive Alport
syndrome.
A number of different COL4A3 and COL4A4 mu-
tations have now been described in TBMN [9, 11–14].
The aim of the present study was to demonstrate the
COL4A3 mutations that caused TBMN in a cohort of
patients who had already been examined for COL4A4
mutations, to determine whether mutations occurred in
the COL4A3/COL4A4 promoter, and to correlate these
mutations with clinical features.
METHODS
Patients
Sixty-two unrelated patients with TBMN were stud-
ied. All had ≥ 30,000 dysmorphic red blood cells/mL on
phase-contrast microscopy of a midstream urine speci-
men [15] on at least two occasions. None had a clinically
detectable hearing loss, and none knew of another fam-
ily member with X-linked or autosomal-recessive Alport
syndrome, renal failure, or inherited hearing loss.
In 49 patients (79%), the diagnosis of TBMN was
confirmed with the ultrastructural demonstration of
diffuse GBM thinning on renal biopsy, and an aver-
age GBM width <250 nm calculated from 50 random
measurements. None of the biopsies had the lamellation
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typical of X-linked Alport syndrome. In 13 cases (21%),
the diagnosis of TBMN was confirmed on a positive fam-
ily history of hematuria alone.
The presence of hypertension, the level of proteinuria,
and the serum creatinine were noted in the index cases at
presentation and at follow-up, and the presence of hema-
turia and proteinuria were noted in the family members
participating in the study.
Linkage to COL4A3/COL4A4 and COL4A5 loci
The families of 42 patients (68%) were examined
for linkage of hematuria to the COL4A3/COL4A4 lo-
cus using methods described previously [4]. Some of
these families have been reported before [4]. Briefly,
affected family members were identified because they
had ≥30,000 dysmorphic red blood cellls/mL on phase-
contrast urinary microscopy. DNA from affected and
unaffected family members was extracted from periph-
eral blood leukocytes or buccal brushings, and ampli-
fied by polymerase chain reaction (PCR) to determine
linkage to the COL4A3/COL4A4 locus using the CA11,
D2S351, D2S401, and PAX3 microsatellite markers and
the COL4A4 Hae III intragenic restriction fragment
length polymorphism [16, 17]. Haplotypes were then con-
structed at the COL4A3/COL4A4 locus for family mem-
bers. Families were usually too small for formal linkage
studies and logarithm of odds (LOD) scores to be mean-
ingful, but the probabilities of hematuria segregating with
the putative disease haplotypes by chance alone were cal-
culated. Linkage to the COL4A5 locus was excluded us-
ing the 2B20, 2B6, and DXS456 microsatellite markers
[18, 19].
Screening for mutations in the COL4A3 exons
For each patient, all 52 COL4A3 exons were ampli-
fied using primers described previously [20] and screened
for mutations using single-stranded conformational poly-
morphism (SSCP) analysis at both room temperature and
4◦C [21]. Patients were examined for mutations regard-
less of whether or not their families were examined and
hematuria segregated with the COL4A3/COL4A4 locus.
Screening for mutations
in the COL4A3/COL4A4 promoter
The region examined began 12 nucleotides upstream of
the COL4A3 start codon and extended 29 bp into intron
1 of the COL4A4 gene [22, 23]. It was amplified in three
parts using the following sets of primers: 5′-CTC AGA
GCC TGG GCG AGT CC-3′ and 5′-GAC ACT GCC
TGG TAA GTT GG-3′; 5′-GGA AGA CGT GGC TCA
GGT CC-3′ and 5′-TCC CGT TAA TCT GGG CAG G-
3′; and 5′-GGC CCT GCC CAG ATT AAC GG-3′ and 5′-
AGC GGT TGC CCC ACC TAT GG-3′. The annealing
temperatures for these reactions were 60◦C, 61◦C, and
58◦C and the products were 244 bp, 307 bp, and 268 bp,
respectively.
SSCP analysis
Both forward and reverse primers for each exon were
end-labelled with c32P-adenosine triphosphate (ATP)
(Geneworks, Adelaide, Australia) using T4 polynu-
cleotide kinase (Geneworks). PCR amplification was
performed in a 5lL reaction containing 25 ng of each
labelled primer, 1 mmol/L deoxynucleotide triphosphate
(dNTP) (Pharmacia, Uppsala, Sweden), 0.5 lL 10 × PCR
× amplification buffer (Gibco BRL, Life Technologies,
Gaithersburg, MD, USA) 0.5 lL 10 × PCR × enhancer
solution (Invitrogen, Carlsbad, CA, USA), 1.25 mmol/L
MgCl2, 0.5 U Taq polymerase (Geneworks), and 20 ng
of genomic DNA from index patients. After the reaction
was complete, 25 lL of SSCP loading buffer (95% for-
mamide, 5 mmol/L NaOH, 0.1% bromophenol blue, and
0.1% xylene cyanol) was added to each tube, and the sam-
ples heated to 95◦C for 5 minutes, and chilled on ice. Five
microliters from each tube was then loaded onto a 6%
nondenaturing polyacrylamide gel, and electrophoresed
in 0.6 × TBE at 2 to 10 W for 3 to 16 hours (depending
on the size of the fragment) at 4◦C. Gels were exposed to
x-ray film for 1 to 20 hours at −80◦C.
Sequencing
All amplicons that demonstrated band shifts were
reamplified (Big Dye Terminator; Perkin-Elmer,
Warrington, UK), purified, and sequenced in both
directions using an automated DNA sequencer. Where
a variant was found, DNA samples from all available
family members were sequenced to determine whether
the variant segregated with hematuria. Mutations were
considered pathogenic if they changed the amino acid
sequence but were not present in 50 nonhematuric
normals.
This project was approved by the Human Research
Ethics Committee of the Austin and Repatriation Medi-
cal Centre, and all participants provided signed, informed
consent to the study.
RESULTS
Mutations and polymorphisms in the COL4A3 gene
Seven novel COL4A3 mutations were demonstrated
in seven of the 62 patients with TBMN (11%) (Table 1).
These were G532C and G584C in exon 25, G596R in exon
26, G695R in exon 28, and IVS 2224 − 11C>T, IVS 2980 +
1G>A and IVS 3518 − 7C>G. None of these changes was
present in 50 nonhematuric normals.
We also demonstrated four novel polymorphisms or
variants (Table 2). These were P116T in exon 6, P690P
in exon 27, and G895G and A899A in exon 33. P1109S
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Table 1. Novel mutations in the COL4A3 gene in thin basement membrane nephropathy (TBMN)
Effect on Clinical Hematuria segregates Frequency in
Exon Mutation coding sequence features in index case with mutation in family controls
25 1594G>T G532C F 24; 240,000 RBC/mL;
proteinuria <200 mg/L;
followed for 12 years
Yes 0/50
1750G>T G584C F 54; 135,000 RBC/mL;
proteinuria < 200 mg/L,
followed for 6 years
Yes 0/50
26 1786G>C G596R F 49; 74,000 RBC/mL;
proteinuria <200 mg/L;
followed for 19 years
Yes 0/50
28 2083G>A G695R F 30; 100,000 RBC/mL;
proteinuria < 200 mg/L;
followed for 13 years
No 0/50
30 2224 − 11C>T IVS F 50; 50,000 RBC/mL;
proteinuria <200 mg/L;
not followed
Not studied 0/50
35 2980 + 1G>A IVS F 16; 160,000 RBC/mL;
proteinuria 2.7 g/day;
followed for 2 years
Yes 0/50
41 3518 − 7C>G IVS F 42; 50,000 RBC/mL;
proteinuria < 200 mg/L;
followed for 5 years
No 0/50
Abbreviations are: RBC, red blood cells; IVS, intervening sequence.
Table 2. Polymorphisms in the COL4A3 gene
Effect on Heterozygosity index
Exon Polymorphism coding sequence of novel polymorphisms
2 IVS2 + 12C>A
127G>C G43R
6 346C>A P116T 0.02
7 422C>T P141L
9 473C>A A158D
485G>A G162E
15 878C>G P293R
17 976G>T D326Y
21 1195T>C L399L
1223G>A R408H
22 1352A>G H451R
23 1452G>A G484G
25 1721T>C L574P
27 2071T>A P690P 0.03
33 2685A>C G895G 0.3
2697C>A A899A 0.3
38 3325C>T P1109S 0.01
40 IVS39 + 18delA
43 3807C>A D1269E
48 4421T>C L1474P
49 4484A>G Q1495R 0.05
Novel polymorphisms are in bold.
had been described previously as a rare variant of
uncertain significance but we found it in two patients
with TBMN and a nonhematuric normal. We also demon-
strated Q1495R, which was previously considered to be
a mutation, in one patient and in one of the 10 normals
whose DNA was sequenced. We therefore consider both
P1109S and Q1495R are polymorphisms. (This is despite
some patients with TBMN having no hematuria [24] and
none of the nonhematuric “normals” having had a renal
biopsy to exclude TBMN). The heterozgosity indices for
the novel polymorphisms are also shown in Table 2.
No mutations or polymorphisms were demonstrated in
the COL4A3/COL4A4 promoter region.
Clinical features associated with mutations
All seven index cases in whom mutations were identi-
fied had hematuria (median 135 × 103 red blood cells/mL,
range 50 to 660) at presentation (Table 1). Only one
had proteinuria >500 mg/day, and this was a 16-year-
old girl with IVS 2980 + 1G>A and 2.7 g protein/day.
None of her three relatives who also had the IVS 2980 +
1G>A mutation had proteinuria >500 mg/day. This girl
has subsequently had a renal biopsy, which showed focal
glomerulosclerosis and glomerular membrane irregular-
ity and lamellation on electron microscopy that suggested
Alport syndrome. Hematuria was present only in the in-
dex case’s father and his family and not in any of her
maternal relatives. X-linked Alport syndrome had been
excluded by linkage studies but this girl may still have had
autosomal-dominant or recessive (assuming her mother’s
disease was subclinical) Alport syndrome.
None of the index cases had hypertension or renal im-
pairment at presentation or increased proteinuria, hyper-
tension, or renal impairment at review after a median of
5 years (range 2 to 12 years).
The families of the index cases with six of the seven mu-
tations were studied. Hematuria was present in all family
members with the G532C, G584C, G596R, and IVS 2980
+ 1G>A mutations but was present in only one of two
and one of four family members with the G695R or IVS
3518 – 7 C>G mutations, respectively.
One patient was of particular interest because she had
a definite mutation in the COL4A3 gene (G695R in exon
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28) as well as a possible mutation in the COL4A4 gene
(G999E in exon 33). Glycine substitutions are usually
pathogenic but the status of G999E is not clear. The pa-
tient was a 30-year-old female with 100,000 urinary red
blood cells/mL, 330 mg/L proteinuria, a blood pressure
of 130/70 mm Hg, and serum creatinine of 0.06 mmol/L
(normal <0.12 mmol/L). She had clinically normal hear-
ing and no lenticonus or retinopathy. Her renal biopsy
contained 12 glomeruli, three of which were completely
sclerosed, and her GBM was uniformly thinned.
DISCUSSION
We have demonstrated seven novel COL4A3 muta-
tions in seven patients with TBMN, as well as four novel
polymorphisms or variants. In addition, we have shown
that P1109S and Q1495R, which were described previ-
ously as a variant of uncertain significance and a muta-
tion, respectively, were actually polymorphisms.
All 62 patients studied had clinical features suggesting
TBMN and nearly 80% had this diagnosis confirmed on
renal biopsy. None of the patients had a family history of
autosomal-recessive Alport syndrome, and patients were
examined for COL4A3 mutations regardless of whether
or not their families were studied or hematuria within
their families segregated with the COL4A3/COL4A4 lo-
cus. X-linked Alport syndrome was excluded on clinical
features, family history, GBM ultrastructural appearance,
and linkage studies.
Although the pathogenicity of any COL4 sequence
variant is difficult to confirm without functional studies,
it is usually considered sufficient to show the variant does
not occur in 50 nonhematuric normals. None of the seven
mutations described here occurred in normals on SSCP.
In addition, all four mutations found in the COL4A3 cod-
ing sequence resulted in glycine substitutions within the
collagenous domain. Mutations in the COL4 genes affect-
ing glycine are usually pathogenic because the substitu-
tion of glycine with larger, more highly charged residues
disrupts the collagen heterotrimer formation. The other
three mutations affected intervening sequences. While it
is difficult to be sure of their pathogenicity, 25% muta-
tions in X-linked Alport syndrome affect splice sites in
the intervening sequences of the COL4A5 gene [25], and
splice site mutations are probably also common in the the
COL4A3 and COL4A4 genes.
None of the COL4A3 mutations we found had been
described previously in the homozygous or compound
heterozygous forms in autosomal-recessive Alport syn-
drome. As well as causing TBMN, heterozygous COL4A3
and COL4A4 mutations cause autosomal-dominant Al-
port syndrome [16, 26, 27]. Autosomal-dominant Al-
port syndrome is characterised by renal failure, hear-
ing loss, and a lamellated GBM, which contrasts with
the hematuria, normal renal function, and thinned GBM
found in TBMN. Too few mutations have been described
in autosomal-dominant Alport syndrome and TBMN
to identify the features that distinguish between these
conditions.
Polymorphisms are common in the COL4A3 and
COL4A4 genes, and more than 20 COL4A3 polymor-
phisms have been described to date [12, 13, 20]. It is
important to identify all these because they may be
mistaken for mutations and patients then misdiagnosed
with TBMN when they actually have X-linked Alport
syndrome.
In this study, no mutations or polymorphisms were
identified in the region of the COL4A3/COL4A4 pro-
moter. Mutations in the promoter and other regulatory
sequences of the COL4A5 gene are also uncommon in
X-linked Alport syndrome. Three reports examining the
COL4A5 promoter region have yielded only one muta-
tion so far, and this resulted in a C to T substitution 113 bp
upstream of the 5′ end of exon 1′ of COL4A6 [abstract;
Kawai S, et al, J Am Soc Nephrol 7:1615A, 1996] [28, 29].
The COL4A3/COL4A4 promoter has neither been stud-
ied previously in TBMN, nor in the autosomal-recessive
and dominant forms of Alport syndrome.
The detection rate of COL4A3 mutations in the 62
patients with TBMN studied here was low (11%, 7/62)
compared with the 50% expected if half the mutations
affected the COL4A3 gene and half the COL4A4 gene.
The rate could be attributed in part to the use of SSCP,
which detects only 80% mutations under optimal con-
ditions, and which does not demonstrate larger deletions
and splice site mutations when the primers are near exon-
intron boundaries. The rate might also be due to the use
of primers that were not designed specifically to detect
splice site mutations. Splice site mutations are common in
X-linked Alport syndrome, but primer design has proven
to be a major limitation to their demonstration [25, 28,
29].
However the mutation detection rate increased to 35%
(7 COL4A3 and 9 COL4A4 mutations in 46 patients)
when both the COL4A3 and COL4A4 genes were ex-
amined. The rate increased further still to 67% (three
COL4A3 and three COL4A4 mutations in nine families)
when only individuals from families where TBMN seg-
regated with the COL4A3/COL4A4 locus were exam-
ined for mutations in these genes. Some individuals from
families where hematuria does not segregate with the
COL4A3/COL4A4 locus will still have mutations in these
genes because the hematuria is incompletely penetrant
[14]. Nevertheless our observation that few COL4A3
or COL4A4 mutations are demonstrated when hema-
turia does not segregate with the COL4A3/COL4A4 lo-
cus suggests the possibility of another genetic locus for
TBMN.
All seven index cases with TBMN in whom mutations
were identified had hematuria but only one had marked
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proteinuria. None of the index cases with these seven mu-
tations had hypertension or renal impairment at presen-
tation or at review. The absence of proteinuria in the fam-
ily members of the patient with the 2980 + 1G>A muta-
tion implies that other genetic and environmental factors
contributed to its demonstration in the index case. Like-
wise, two mutations (G695R, IVS 3518 – 7 C>G) were
not necessarily associated with hematuria in all family
members. Finally, we described an individual with possi-
ble compound heterozygous mutations in the COL4A3
and COL4A4 genes whose clinical features were consis-
tent with TBMN rather than with autosomal-recessive
Alport syndrome.
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